Copy to clipboard 
Swiss surgical fixation company Medartis posted 2018 revenue of CHF 121.3MM (USD $121.9MM), +15.5% vs. 2017. After completing its 2018 IPO, the company went on to drive double-digit growth nearly across the board for its product lines and geographies. Medartis expects double-digit sales growth once again in 2019 based on new products and continued strong sales in EMEA.
The company’s largest business, upper extremity fixation, grew 13% on the strength of hand, wrist and elbow products. Lower extremity fixation, Medartis’ newest segment, grew 28% for the year. Sales of their craniomaxillofacial products as well as instruments, classified as Other below, grew 16%. The company launched proximal humerus plates for the treatment of shoulder fractures in late 2018 and plans to launch a new generation of CMF products in 2020.
Medartis’ investments in U.S. management and sales force showed benefits, with nearly 11% growth in North America. The company’s largest region, EMEA, grew 15% while Australia and Japan drove Asia Pacific to 9.9% growth. Rest of World grew 10% organically, with the remainder coming from Medartis’ 2017 acquisition of Brazilian distributor Extera.
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows.
| FY18 | FY17 | $ Change | % Change | |
| Trauma | $110.9 | $96.1 | $14.8 | 15.4% |
| Other (CMF) | $11.0 | $9.5 | $1.5 | 16.1% |
| Total | $121.9 | $105.5 | $16.4 | 15.5% |
Sales by geographic region:
| Geographic Region | FY18 | FY17 | $ Change | % Change |
| US | $19.4 | $17.5 | $1.9 | 10.9% |
| Ex-US | $102.5 | $88.1 | $14.5 | 16.4% |
| EMEA | $66.7 | $58.0 | $8.6 | 14.9% |
| Asia Pacific | $22.9 | $20.8 | $2.1 | 9.9% |
| Rest of World | $12.9 | $9.2 | $3.8 | 40.8% |
| Total | $121.9 | $105.5 | $16.4 | 15.5% |
Sources: Medartis; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Swiss surgical fixation company Medartis posted 2018 revenue of CHF 121.3MM (USD $121.9MM), +15.5% vs. 2017. After completing its 2018 IPO, the company went on to drive double-digit growth nearly across the board for its product lines and geographies. Medartis expects double-digit sales growth once again in 2019 based on new products and...
Swiss surgical fixation company Medartis posted 2018 revenue of CHF 121.3MM (USD $121.9MM), +15.5% vs. 2017. After completing its 2018 IPO, the company went on to drive double-digit growth nearly across the board for its product lines and geographies. Medartis expects double-digit sales growth once again in 2019 based on new products and continued strong sales in EMEA.
The company’s largest business, upper extremity fixation, grew 13% on the strength of hand, wrist and elbow products. Lower extremity fixation, Medartis’ newest segment, grew 28% for the year. Sales of their craniomaxillofacial products as well as instruments, classified as Other below, grew 16%. The company launched proximal humerus plates for the treatment of shoulder fractures in late 2018 and plans to launch a new generation of CMF products in 2020.
Medartis’ investments in U.S. management and sales force showed benefits, with nearly 11% growth in North America. The company’s largest region, EMEA, grew 15% while Australia and Japan drove Asia Pacific to 9.9% growth. Rest of World grew 10% organically, with the remainder coming from Medartis’ 2017 acquisition of Brazilian distributor Extera.
ORTHOWORLD estimates segment sales and growth on an as-reported basis as follows.
| FY18 | FY17 | $ Change | % Change | |
| Trauma | $110.9 | $96.1 | $14.8 | 15.4% |
| Other (CMF) | $11.0 | $9.5 | $1.5 | 16.1% |
| Total | $121.9 | $105.5 | $16.4 | 15.5% |
Sales by geographic region:
| Geographic Region | FY18 | FY17 | $ Change | % Change |
| US | $19.4 | $17.5 | $1.9 | 10.9% |
| Ex-US | $102.5 | $88.1 | $14.5 | 16.4% |
| EMEA | $66.7 | $58.0 | $8.6 | 14.9% |
| Asia Pacific | $22.9 | $20.8 | $2.1 | 9.9% |
| Rest of World | $12.9 | $9.2 | $3.8 | 40.8% |
| Total | $121.9 | $105.5 | $16.4 | 15.5% |
Sources: Medartis; ORTHOWORLD estimates.
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
